Overview

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
Phase:
PHASE3
Details
Lead Sponsor:
Materia Medica Holding